Notice of Pendency of Class Action on Behalf of Purchasers of the Common Stock of Interneuron Pharmaceuticals Inc.
Wednesday, October 15, 1997 06:41 PM ET
BOSTON--On Oct. 15, 1997, the law firm of Wolf Haldenstein Adler Freeman & Herz LLP filed a class action lawsuit in the United States District Court for the District of Massachusetts on behalf of all purchasers of the common stock of Interneuron Pharmaceuticals Inc. ("Interneuron") during the period March 1, 1997 through Sept. 15, 1997 (the "Class Period").
The complaint charges Interneuron and certain of its directors and officers with violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5 for, among other things, concealing material adverse non-public information from the public by failing to disclose evidence of heart valve abnormalities in patients taking Interneuron's weight loss medication Redux (dexfenfluramine).
The Plaintiffs seek to recover damages on behalf of Class members and are represented by the law firms of Wolf Haldenstein Adler Freeman & Herz LLP and Berman DeValerio & Pease, LLP, who have had extensive experience in securities class action litigation and have obtained over $1 billion in awards for their clients.
If your are a member of the class described above, you may no later 60 days from Oct. 9, 1997, move the Court to serve as lead plaintiff of the class, if you so choose. In order to serve as lead plaintiff, however, you must meet certain legal requirements.
If you wish to discuss this action or have any questions concerning this notice or your rights, please contact any of the following:
Wolf Haldenstein Adler Freeman & Herz LLP
270 Madison Ave., New York, N.Y. 10016
Robert Abrams, Esq. or Michael Miske
800/575-0735 |
